Does coffee protect against Parkinson's?

Does drinking coffee reduce my risk of getting Parkinson's?

Regular coffee drinkers show a lower risk of developing Parkinson's disease, but this does not prove coffee prevents the condition. A meta-analysis pooling nine cohort studies, which are long-term observational projects tracking healthy populations, found that regular caffeine intake was associated with a 20 per cent lower risk of developing Parkinson's. This analysis yielded a hazard ratio of 0.797, which measures the relative likelihood of an event occurring in one group compared to another over time.

Genetic analyses suggest no direct causal link exists. A Mendelian randomisation study, a method using genetic variants to mimic a clinical trial, examined data from up to 939,908 people alongside 9,581 Parkinson's cases and 33,245 controls. This study found no causal relationship between drinking coffee and disease risk, reporting an odds ratio of 1.032 per cup per day.

Uncontrolled lifestyle factors may explain the observational link. People who drink coffee regularly may differ from non-drinkers in their exercise levels, alcohol use, or exposure to environmental pesticides. Additionally, Parkinson's develops silently for decades, meaning observational studies using dietary questionnaires may misclassify who is in the early stages of the disease.

Can coffee slow down my Parkinson's now that I have been diagnosed?

Clinical evidence does not show that caffeine slows down Parkinson's disease or protects brain cells. Although laboratory experiments on rodents suggest caffeine might protect dopaminergic cells, which are the brain cells that produce dopamine, these biological effects have not been proven in clinical trials on humans. Human trials show that caffeine tablets do not modify the long-term course of the disease.

Observational studies of patients already diagnosed show weak and inconsistent results. A meta-analysis combining four cohort studies tracking early-stage patients for up to 10.3 years reported a slight association between regular caffeine consumption and slower disease progression. However, these studies used inconsistent measures for progression, such as when a patient first needed levodopa, which is a standard medication used to replace dopamine.

Rigorous clinical trials fail to show any long-term benefit. The Café-PD trial, a multicentre, double-blind randomised controlled trial, tracked 121 patients who had been diagnosed with Parkinson's for one to eight years. Sixty patients received 200 milligrams of caffeine twice a day, while 61 received a placebo. After six months, there was no clinically meaningful difference in motor symptoms, and caffeine was associated with a slight increase in dyskinesia, which are involuntary muscle movements.

Is it definitely the caffeine in the coffee that helps?

Nobody has tested pure caffeine tablets in a long-term trial to see if they prevent the disease. Our knowledge comes almost entirely from observational cohort studies where participants drank coffee rather than pure compounds. A meta-analysis of 13 cohort studies found that researchers could not isolate specific coffee ingredients, such as eicosanoyl-5-hydroxytryptamide, a compound believed to protect against neurodegeneration, because standard dietary questionnaires do not measure them.

The primary evidence pointing specifically to caffeine is that tea shows a similar protective association. Because tea also contains caffeine, researchers suggest this compound is the key protective agent. At the cellular level, caffeine acts as an adenosine A2A receptor antagonist, which is a blocker that binds to receptors on brain cells to prevent excitotoxicity, meaning nerve cell damage caused by over-excitation.

Short-term clinical trials use decaffeinated coffee and pure tablets to isolate caffeine's effects. A crossover trial, which is a study design where participants receive different treatments in sequence, evaluated 24 patients with Parkinson's and 42 healthy older adults. The trial compared single doses of 100-milligram caffeine tablets dissolved in decaffeinated coffee against plain decaffeinated coffee, but was limited because it only looked at immediate effects on goal-directed attention.

Does coffee protect women and men in the same way?

The evidence on how gender and hormone replacement therapy change coffee's effect on Parkinson's risk is extremely limited. A meta-analysis of nine prospective cohort studies found that regular caffeine consumption is associated with a 20 per cent lower risk of developing Parkinson's. However, only two of these studies separated their findings to compare men and women, showing no significant difference, and only one study examined hormone replacement therapy.

While hormone therapy's interaction with coffee remains unresolved, its direct link to Parkinson's risk has been studied separately. A meta-analysis of 14 observational studies involving 753,749 participants found that combined estrogen-progestin therapy is associated with an increased Parkinson's risk, showing a relative risk of 1.40. Estrogen-only therapy showed no significant association, with a relative risk of 1.01, but neither of these reviews analysed how these risks interact with coffee.

What happened when trials tried to use caffeine as a treatment?

Clinical trials testing caffeine tablets have failed to show a lasting, meaningful benefit for people already living with Parkinson's. In the Café-PD trial, researchers randomised 121 participants to receive either 200 milligrams of caffeine twice daily or a placebo for up to 18 months. At six months, the objective motor scores of the 60 participants taking caffeine showed no improvement compared to the 61 taking the placebo, and caffeine was linked to slightly worse cognitive scores.

Smaller and shorter trials offer conflicting but highly limited results. A double-blind trial in Indonesia evaluated 27 participants, dividing them into 15 who received 50 milligrams of caffeine twice daily and 12 who received a placebo. While it reported motor improvements in 80 per cent of the caffeine group after three weeks, this trial was severely weakened by its tiny size, short duration, and the confounding effect of trihexyphenidyl, a prescription medication for tremors.

Nobody has found a way to translate daily coffee drinking into a standard therapeutic dose. Daily beverages vary wildly in their caffeine content, and individual metabolism is highly inconsistent due to genetic differences. Additionally, because caffeine acts as a temporary chemical stimulant, nobody has found a way to distinguish a temporary boost in alertness from a true slowing of brain cell loss.

What this does not show

Clinical evidence does not support using coffee or caffeine to improve Parkinson's disease motor symptoms. The Café-PD trial, registered under the number NCT01738178, randomised 60 patients to receive 200 milligrams of caffeine twice daily and 61 patients to a placebo for up to 18 months. It found no significant difference in motor symptoms between the groups, measuring a negligible difference of just -0.48 points on the MDS-UPDRS-III, which is a standard motor rating scale.

Caffeine tablets may actually worsen cognitive function and increase involuntary movements. In the Café-PD trial, patients taking caffeine scored an average of 0.66 points lower on the Montreal Cognitive Assessment than the placebo group and experienced a slight increase in dyskinesia. A single-blind crossover trial in 24 patients and 44 healthy controls found that a single 100-milligram dose of caffeine impaired visual temporal attention, which is the ability to identify single items in a rapid sequence, despite minor improvements in basic reaction times.

Positive findings rest on tiny, poorly controlled studies. An Indonesian trial reporting motor benefits after three weeks evaluated only 15 patients on a caffeine adjuvant and 12 on a placebo, and statistical analysis showed that trihexyphenidyl, a tremor medication, heavily confounded the results. Furthermore, population studies cannot prove a causal link or establish a protective dose because they rely on unreliable dietary questionnaires and fail to control for lifestyle factors like exercise and diet.

This review provides you with the specific clinical data showing that caffeine does not slow Parkinson's symptoms or offer proven long-term protection. You can use these trial results to discuss with your specialist whether altering your daily coffee intake is worth pursuing based on your personal symptom profile.